Firmagon (degarelix)
- Region
- 🇪🇺 EU
- Active substance
- degarelix
- Company
- Ferring Pharmaceuticals A/S
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms
- EU approval
- Tue 17 Feb 2009
- Application
- EMEA/H/C/000986
- ATC
- L02BX02
- Official record
- www.ema.europa.eu
Indication
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Degarelix Accord Authorised · Accord Healthcare S.L.U.
Follow Firmagon
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.